Intrahepatic cholestasis of pregnancy-current achievements and unsolved problems.
Intrahepatic cholestasis of pregnancy (ICP) is the most common pregnancy-related liver disorder. Maternal effects of ICP are mild; however, there is a clear association between ICP and higher frequency of fetal distress, preterm delivery, and sudden intrauterine fetal death. The cause of ICP remains elusive, but there is evidence that mutations in genes encoding hepatobiliary transport proteins can predispose for the development of ICP. Recent data suggest that ursodeoxycholic acid is currently the most effective pharmacologic treatment, whereas obstetric management is still debated. Clinical trials are required to identify the most suitable monitoring modalities that can specifically predict poor perinatal outcome. This article aims to review current achievements and unsolved problems of ICP.
Department of Gastroenterology, Kaunas University of Medicine, Kaunas 50009, Lithuania. jukond@takas.lt
Jurate
J
Kondrackiene
Limas
L
Kupcinskas
D002780:Cholestasis, Intrahepatic / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D011256:Pregnancy Outcome; D012307:Risk Factors; D016896:Treatment Outcome